Patients with IBD are approximately 6 times more likely to develop colorectal cancer than those without IBD
GLP-1 agonist drugs like Ozempic work by stimulating the GLP-1 receptor in the body, which helps increase insulin secretion, reduce glucagon release, slow down stomach emptying, and promote a feeling of fullness
Heres what to watch out for: Persistent Fatigue Feeling drained even after a whole nights rest
Patients receive transparency: all medications arrive with pharmacy credentials, ingredient verification, and quality documentation
Unlike the dual agonist Tirzepatide (GLP-1/GIP) or the mono-agonist Semaglutide (GLP-1), Retatrutide adds glucagon-receptor activation, which in studies is associated with additional increases in energy expenditure, lipolysis and reduced liver fat
As an alternative strategy to target IGF signaling, results of phase 1 clinical trials of the dual IGF1/2-neutralizing antibodies have been reported, while no results of phase 2/3 trials in cancer therapy have been reported [156, 157]